Showing results (31-40 of 720) with videos related to

Sort By:
Pageof 72
The Lancet. Haematology|October 10, 2022
Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendationsGuillermo Garcia-Manero
The Lancet. Haematology|October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label studyThomas Martin, Yi Lin, Mounzer Agha, et al.
The Lancet. Haematology|February 25, 2021
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trialJeff P Sharman, Danielle M Brander, Anthony R Mato, et al.
The Lancet. Haematology|February 26, 2021
Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registryRoni Shouval, Joshua A Fein, Myriam Labopin, et al.
The Lancet. Haematology|February 26, 2021
Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directionsKatharina Baur, Andreas S Buser, Laura Infanti, et al.
The Lancet. Haematology|August 7, 2019
Longer-term efficiency and safety of increasing the frequency of whole blood donation (INTERVAL): extension study of a randomised trial of 20 757 blood donorsStephen Kaptoge, Emanuele Di Angelantonio, Carmel Moore, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialSaad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, et al.
The Lancet. Haematology|August 6, 2019
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trialZhiling Yan, Jiang Cao, Hai Cheng, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
Pageof 72